ArticleAvicenna journal of medical biotechnology
Clinically Significant Dysregulation of
Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Clinical significance of miRNAs and exosomal miRNAs in non-small cell lung cancer: diagnostic, prognostic, and therapeutic perspectives.Journal of human genetics · 2026Review
- The TMPO-AS1/hsa-let-7b-5p regulatory axis shapes transcriptional heterogeneity and immune landscape in lung adenocarcinoma.Cell division · 2026Article
- Long noncoding RNA TMPO-AS1 upregulates chromosomal passenger complex expression to promote cell proliferation in lung cancer via sponging microRNA let-7b-5p.Cell division · 2025Article
- A novel approach in the identification of microRNAs in malignant pleural effusion for lung cancer diagnosis.Oncology reviews · 2025Review
- Integration of miRNA expression analysis of purified leukocytes and whole blood reveals blood-borne candidate biomarkers for lung cancer.Epigenetics · 2024Article
- Identification of novel potential drugs and miRNAs biomarkers in lung cancer based on gene co-expression network analysis.Genomics & informatics · 2023Article
- Using the Precision Lasso for gene selection in diffuse large B cell lymphoma cancer.Journal of the Egyptian National Cancer Institute · 2023Article
- Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.Biomedicines · 2022Review
- CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer.Advanced pharmaceutical bulletin · 2022Review
- A novel three-microRNA signature for predicting survival in patients with nasopharyngeal carcinoma.Journal of dental sciences · 2022Article
- miR-30d-5p: A Non-Coding RNA With Potential Diagnostic, Prognostic and Therapeutic Applications.Frontiers in cell and developmental biology · 2022Review
- NcRNA-regulated CAPZA1 associated with prognostic and immunological effects across lung adenocarcinoma.Frontiers in oncology · 2022Article
- Using Network Distance Analysis to Predict lncRNA-miRNA Interactions.Interdisciplinary sciences, computational life sciences · 2021Article
- Epithelial Membrane Protein 2 Suppresses Non-Small Cell Lung Cancer Cell Growth by Inhibition of MAPK Pathway.International journal of molecular sciences · 2021Article
- Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.International journal of molecular sciences · 2021Article
- MicroRNAs may provide new strategies in the treatment and diagnosis of diabetic retinopathy: Importance of VEGF.Iranian journal of basic medical sciences · 2021Review
- Role of microRNAs in Lung Carcinogenesis Induced by Asbestos.Journal of personalized medicine · 2021Review
- Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.BMC cancer · 2020Article
- MicroRNA-30d-5p promotes ovarian granulosa cell apoptosis by targeting Smad2.Experimental and therapeutic medicine · 2020Article
- Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.Clinical and translational gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cyclin E2 (CYCE2) is an important regulator in the progression and development of NSCLC, and its ectopic expression promoted the proliferation, invasion, and migration in several tumors, including Non-Small Cell Lung Cancer (NSCLC). However, the upregulation of CYCE2 in NSCLC cells suggested that it has a key role in tumorigenicity. In addition, the RAS family proteins as oncoproteins were activated in many major tumor types and its suitability as the therapeutic target in NSCLC was proposed. Considering the crucial role of microRNAs, it was hypothesized that altered expression of
methodReal-time RT-PCR approach could evaluate the expression alteration of
results
conclusionTogether, these results suggest a possible tumor suppressor role for
Indexed as
Identifiers
29849986PMC5960066W2789238214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.